{"news": [{"date": "20240409203214", "headline": "Rose's Income Garden Portfolio With 7 March Dividend Raises/ Portfolio Yield 6%", "summary": "Rose's Income Garden (RIG) portfolio consists of 83 defensive stocks prioritizing income, with a 6% yield. Read more on the portfolio here."}, {"date": "20240410010200", "headline": "Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Bausch Health Companies (BHC) and Ultragenyx Pharmaceutical (RARE)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410072700", "headline": "This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?", "summary": "GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema"}, {"date": "20240410103715", "headline": "Amgen : Chairman and CEO Letter and Amgen Inc. 2023 Annual Report", "summary": "LETTER TO SHAREHOLDERS 2023 Robert A. Bradway ..."}, {"date": "20240410104408", "headline": "Amgen : CEO Bob Bradway's 2023 Letter to Shareholders", "summary": "Amgen performed well in 2023, serving millions of patients around the world with our innovative, life-changing medicines; advancing many promising new first-in-class molecules in our pipeline;..."}, {"date": "20240411025600", "headline": "Early notable gainers among liquid option names on April 11th", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411043600", "headline": "Interesting AMGN Put And Call Options For May 31st", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411060000", "headline": "Is Amgen Stock a Buy?", "summary": "Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice."}, {"date": "20240411092348", "headline": "What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences", "summary": "Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept. Read more on VRTX and ALPN stocks here."}, {"date": "20240411160018", "headline": "Amgen (AMGN) Laps the Stock Market: Here's Why", "summary": "In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day."}, {"date": "20240412020100", "headline": "Amazon Is Positioned as the Foundation for Retail and Technology Infrastructure", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412021400", "headline": "Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412053400", "headline": "Looking At Amgen's Recent Unusual Options Activity", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240413035600", "headline": "AbbVie keeps Humira market share near 100% despite biosimilars: report", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240414222544", "headline": "Amgen: The Giant With An Impressive Pipeline", "summary": "Amgen's acquisition of Horizon Therapeutics transforms it into a leader in rare disease treatments. Click here to read why AMGN stock is a Buy."}, {"date": "20240415002300", "headline": "Amgen price target lowered by $10 at TD Cowen, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415004100", "headline": "Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415010200", "headline": "Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415013300", "headline": "Amgen, Shell And More On CNBC's 'Final Trades'", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415021500", "headline": "Amgen: I Prefer To Chase Value And Dividends", "summary": ""}, {"date": "20240415070711", "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know", "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects."}, {"date": "20240415130727", "headline": "3 Stocks to Buy Low Today With High Hopes for Tomorrow", "summary": "Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal. However, the challenge lies not only in identifying overvalued and undervalued stocks trading at appreciated or depressed prices but also in those with promising potential.There may be several reasons why undervalued stocks do not reflect their"}, {"date": "20240416052800", "headline": "As more rare disease therapies launch, their prices are rising", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416100411", "headline": "Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker", "summary": "Gastric and gastroesophageal junction cancers, otherwise known as stomach cancer, is the fourth leading cause of cancer-related death worldwide, with the highest incidence rates occurring in Eastern..."}, {"date": "20240416102442", "headline": "FHLC: Healthcare Dashboard For April", "summary": "Fidelity MSCI\u00c2\u00a0Health Care\u00c2\u00a0Index ETF is an alternative to XLV for long-term investors. Read this article to learn more about FHLC ETF."}, {"date": "20240416143000", "headline": "The 3 Best Biotech Stocks to Buy Now: Q2 Edition", "summary": "Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities. We\u2019re even seeing big opportunities in cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. We can even look at the impact artificial intelligence could have on he"}, {"date": "20240416152600", "headline": "AMGEN TO PRESENT TEZSPIRE\u00ae PHASE 2A COPD DATA AT ATS 2024", "summary": "Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE\u00ae (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT."}, {"date": "20240416194100", "headline": "Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416202600", "headline": "Barclays Keeps Their Sell Rating on Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416224600", "headline": "Buy Rating on Amgen: Tezspire\u2019s Market Potential in COPD Treatment Undervalued", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417012800", "headline": "Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417023000", "headline": "Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever", "summary": "Not every business in operation today is built to thrive -- or even last -- indefinitely. These are."}, {"date": "20240417023200", "headline": "CVS favors Humira copycats hurting AbbVie\u2019s market share: Evercore", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417035845", "headline": "AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024", "summary": "THOUSAND OAKS - Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE in chronic obstructive pulmonary disease , which were accepted for presentation in the..."}, {"date": "20240417053000", "headline": "Analyst Holds on Amgen\u2019s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417053000", "headline": "Can This High-Yield Dividend Stock Keep Beating the S&P 500?", "summary": "Amgen's shares have come under pressure this year, making it a compelling bargain buy."}, {"date": "20240417060000", "headline": "Coming FDA Approvals Could Send These 3 Drug Stocks Soaring", "summary": "In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug s"}, {"date": "20240417060000", "headline": "Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble", "summary": "When the term blue chip is thrown around, many investors hear synonyms like stability and success. Other definitions limit blue-chip stocks to the 30 companies comprising the Dow Jones Industrial Average. However, blue chip stocks should be considered as those representing long-running and well-established companies that prioritize their financial health. Moreover, these companies typically command a market capitalization numbering in the billions or even trillions of dollars. This ensures both"}, {"date": "20240417064310", "headline": "Amgen : First Cancer Diagnosis Led to a Dark Place\u2014Aiding Another Helped Lift Him Out of It", "summary": "Otis Wilson Jr. had been where Robert Hairston was and knew how he was feeling. And what he was thinking about. Death. [...]This is an abstract of the document. To keep reading, click here and get..."}, {"date": "20240417160017", "headline": "Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights", "summary": "Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close."}, {"date": "20240418023300", "headline": "See Which Of The Latest 13F Filers Holds Amgen", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419024800", "headline": "How Is The Market Feeling About Amgen?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419051400", "headline": "The Dividend Goldmine: 3 Shining Stocks With Growing Payouts", "summary": "There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give investors a means to achieve solid returns and reliable income streams. Three exceptional businesses light up the scene in this domain with their steadfast dedication to growth and shareholder rewards. The first one, a key player in the communication services industry, demonstrates a strategic shift t"}, {"date": "20240420013100", "headline": "Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240420060300", "headline": "THQ: Collecting A High Yield From Increased Medical Spending", "summary": "abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here."}, {"date": "20240421010700", "headline": "13 new obesity drugs could hit the market by 2029 amid surging demand", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421184139", "headline": "SCHD: If You've Won The Game, Take A Little Off The Top", "summary": "SCHD is a great capital gains storage for positions that may be getting over-concentrated in your portfolio. Read why SCHD ETF is a Buy."}, {"date": "20240422012800", "headline": "Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422034800", "headline": "March 2025 Options Now Available For Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422041000", "headline": "Dividend yield and growth stock list by Goldman", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422055900", "headline": "Goldman\u2019s debt issuers stocks basket", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422060300", "headline": "Gilead Sciences: Some Signs Of An Impending Bottom", "summary": "Gilead Sciences\u00e2\u0080\u0099 stock underperformed market substantially over past decade. It offers a high 4.61% dividend yield. Read my earnings analysis of GILD stock here."}, {"date": "20240422091059", "headline": "10 Best Performing Biotech ETFs in 2024", "summary": "In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for [\u2026]"}, {"date": "20240422155017", "headline": "Why Amgen (AMGN) Outpaced the Stock Market Today", "summary": "In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day."}, {"date": "20240422221209", "headline": "The Pleading Standard For Complex Technology? It's Complex.", "summary": "Can a patentee really just take a pass on alleging that an accused product meets a limitation in an asserted claim, even where the case involves complex technology? That's the upshot of the court's..."}, {"date": "20240423233100", "headline": "Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424080415", "headline": "Amgen : How Amgen\u2019s Real-World Evidence Is Changing The Future of Patient Care in Psoriatic Disease", "summary": "At Amgen, our unique real-world evidence capabilities in our Center for Observational Research are breaking new ground in our knowledge of plaque psoriasis and psoriatic arthritis. Cynthia Deignan and..."}, {"date": "20240424100500", "headline": "Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?", "summary": "While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter."}, {"date": "20240424214000", "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425014300", "headline": "AstraZeneca rises as oncology business drives Q1 beat", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425043000", "headline": "Spring Awakening: 3 Dow Stocks Emerging from Hibernation", "summary": "The last time I spoke about the top blue-chip stocks to buy on dips, I highlighted opportunity in the 2024 Dogs of the Dow. As I noted at the time, \u201cMade up of the hardest-hit Dow stocks, which also pay out hefty dividend yields, you buy the Dogs at the start of the year, and cash out at the end of the year with hopeful wins in hand. In 2023, the Dogs of the Dow returned about 10.1%, as compared to the 14.4% gains on the overall Dow Jones Industrial Average.\u201d As for 2024 year to date, the top Do"}, {"date": "20240425080205", "headline": "Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for", "summary": "Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."}, {"date": "20240425093424", "headline": "20 Fastest Growing Health Tech Companies in the World", "summary": "In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital [\u2026]"}, {"date": "20240425123359", "headline": "CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town", "summary": "CytomX' main pipeline candidate, CX-904, is a bispecific probody targeting EGFR and CD3, being assessed in a phase 1 trial. Read why CTMX stock is rated a buy."}, {"date": "20240425200600", "headline": "Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425230000", "headline": "O'Keefe Stevens Advisory Q1 2024 Investor Letter", "summary": "After discussing GrafTech's challenges throughout 2022 and 2023, Groundhog Day came early in 2024, with the stock declining 39% in January."}, {"date": "20240426020300", "headline": "Amgen announces imminent submission of MAA to EMA for teprotumumab", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426033835", "headline": "Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza", "summary": "By Colin Kellaher Amgen plans to seek European regulatory approval for the sale of its blockbuster Tepezza treatment for thyroid eye disease. The Thousand Oaks, Calif., biotechnology..."}, {"date": "20240426070000", "headline": "AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY", "summary": "Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia"}, {"date": "20240426095640", "headline": "Diving Into Deciphera Pharmaceuticals", "summary": "Deciphera's Vimseltinib is expected to make significant progress in the TGCT indication. Check out my\u00c2\u00a0investment analysis around DCPH stock here."}, {"date": "20240426161717", "headline": "A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed", "summary": "Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news."}, {"date": "20240426204100", "headline": "Amgen\u2019s Blincyto data send Cullinan higher", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240427234458", "headline": "Roche: Value Remains Despite Covid-19 Revenue Growth Loss", "summary": "Vabysmo and Phesgo are still strong growth drivers for Roche (RHHBY) going forward. Find out why I rate the stock a strong buy."}, {"date": "20240428010300", "headline": "Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428012226", "headline": "Wall Street Breakfast: The Week Ahead", "summary": "This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events."}, {"date": "20240428060400", "headline": "J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428201200", "headline": "Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled (update)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429000100", "headline": "Options Volatility and Implied Earnings Moves This Week, April 29 \u2013 May 02, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429025130", "headline": "Immatics N.V.: An Intriguing Developmental Concern", "summary": "Immatics N.V. is expected to release clinical data on all four of its candidates in 2024. Read more to see a full investment analysis of IMTX stock."}, {"date": "20240429042500", "headline": "AMGN Crosses Above Key Moving Average Level", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429055300", "headline": "Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429065600", "headline": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429071600", "headline": "Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics", "summary": "Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics."}, {"date": "20240429103500", "headline": "What's in the Cards for Amgen (AMGN) This Earnings Season?", "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs."}, {"date": "20240429140000", "headline": "AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS", "summary": "Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team."}, {"date": "20240429160108", "headline": "Amgen : Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products", "summary": "Amgen Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to..."}, {"date": "20240429200358", "headline": "Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation", "summary": "By Ian Walker Sandoz Group said that it has reached agreement with Amgen in the patent dispute over the company's denosumab biosimilars products, paving the way for it to launch its bone..."}, {"date": "20240429203500", "headline": "Sandoz, Amgen reach agreement resolving patent litigation over biosimilars", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429223800", "headline": "Sandoz, Amgen to resolve all patent disputes relating to denosumab biosimilars", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429232800", "headline": "Sandoz reaches agreement with Amgen over patent dispute", "summary": "Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.  The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement.  \"The terms of the agreement will not impact our previously disclosed 2024 guidance,\" Sandoz said."}, {"date": "20240430002200", "headline": "Amgen (AMGN) Gets a Buy from Truist Financial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430005700", "headline": "Amgen settlement with Sandoz a positive, says Jefferies", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430010200", "headline": "Analysts\u2019 Top Healthcare Picks: Laboratory (LH), Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430040600", "headline": "Dow drops 150 points on losses for Caterpillar, Amgen shares", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430092000", "headline": "Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?", "summary": "Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week."}, {"date": "20240430115459", "headline": "Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab", "summary": "Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosimilars. Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. \u201cThe terms of the agreement will not impact our previously disclosed 2024 guidance,\u201d Sandoz said. Sandoz received FD"}, {"date": "20240430200400", "headline": "Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501022100", "headline": "BMO sees CytomX rallying after 'surprise' data announcement", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501024900", "headline": "Global company events calendar", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501034900", "headline": "CytomX surges on upcoming data for Amgen-partnered cancer drug", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501044400", "headline": "Moody\u2019s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501044900", "headline": "Amgen Q1 Earnings Preview: Obesity treatment updates to be the focus this season", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501050000", "headline": "AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024", "summary": "Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented."}, {"date": "20240501055859", "headline": "Amgen investors await weight-loss drug data", "summary": "Amgen investors eyeingdramatic share price gains for rivals with successful obesitydrugs will be focused on any updates the biotech company mayprovide on its own weight-loss drug candidates when it..."}, {"date": "20240501110744", "headline": "Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet", "summary": "Amgen Inc. shares dropped 20% due to a below-consensus outlook. Their obesity candidate MariTide may be their biggest revenue producer. Click for my AMGN update."}, {"date": "20240501183500", "headline": "GLOBAL BRIEFING: Federal Reserve notes \"lack of progress\" on inflation", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501210200", "headline": "Amgen reports Q1 adjusted EPS $3.96, consensus $3.87", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501210400", "headline": "Amgen narrows FY24 adjusted EPS view to $19.00-$20.20 from $18.90-$20.30", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501210600", "headline": "Arrowhead earns $50M milestone from Royalty Pharma", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501210900", "headline": "Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501212000", "headline": "Amgen in charts: Major drug sales grow at slower pace Y/Y, rev from Enbrel dips in Q1", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501212000", "headline": "Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501223300", "headline": "Market Today: Coinbase and Block Lead Earnings Surprises, Boosting Tech Stocks", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501224500", "headline": "Amgen stock rallies 13% on weight-loss drug updates, tweaked guidanace", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501225100", "headline": "Amgen stock rallies 13% amid weight-loss drug updates, tweaked guidance", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501231200", "headline": "Amgen \u2018very encouraged\u2019 by preliminary data from weight-loss drug trial, stock jumps", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501233608", "headline": "Amgen : Getting Older and Still Standing Tall", "summary": "Osteoporosis is a silent condition, meaning that bone loss can occur without symptoms, and typically individuals do not experience symptoms until a bone break.1 Because of this, many women may not..."}, {"date": "20240501234400", "headline": "Amgen \u2018very encouraged\u2019 by preliminary data from weight-loss-drug trial, as stock jumps", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501234900", "headline": "Fly Intel: After-Hours Movers", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501235500", "headline": "Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502000600", "headline": "Options Volatility and Implied Earnings Moves Today, May 02, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502041200", "headline": "Apple, Coinbase, Block, Amgen, Tesla: Why These 5 Stocks Are On Investors' Radars Today", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502063400", "headline": "Amgen's Options: A Look at What the Big Money is Thinking", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502064100", "headline": "Wall Street Inches Up Post Fed; Chipmakers Rebound; Gold, Crude Falter: What's Driving Market Thursday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502064500", "headline": "Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502065000", "headline": "Notable companies reporting after market close", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502093205", "headline": "CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling", "summary": "CytomX Therapeutics is gearing up for a major inflection point, where it will release data from an ongoing phase 1a dose-escalation study. Read more here."}, {"date": "20240502100100", "headline": "Amgen first-quarter profit dips 1%, revenue rises 22%", "summary": "Amgen reported a slightlylower first-quarter profit on Thursday, citing higher operatingand interest expense from its recent acquisition of rare diseasedrugmaker Horizon Therapeutics, partially..."}, {"date": "20240502101015", "headline": "Amgen: Q1 Earnings Snapshot", "summary": "THOUSAND OAKS, Calif. \u2014 THOUSAND OAKS, Calif. \u2014 Amgen Inc. on Thursday reported a first-quarter loss of $113 million, after reporting a profit in the same period a year earlier. The..."}, {"date": "20240502104319", "headline": "Amgen Posts Higher 1Q Revenue, Swings to Loss", "summary": "By Paul Ziobro Amgen posted higher revenue, but swung to a first-quarter loss, driven by a drop in value of its investment in BeiGene and other expenses from its Horizon Therapeutics..."}, {"date": "20240502105200", "headline": "TOP NEWS: Amgen posts first quarter loss despite uptick in sales", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502140100", "headline": "AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS", "summary": "Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024."}, {"date": "20240502140226", "headline": "Amgen 'encouraged' by weight-loss drug interim data, shares jump", "summary": "(Reuters) -Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide and will no longer develop its oral obesity candidate AMG786.  Shares of Amgen surged 13% in after hours trading.  Investors are focused on Amgen's pipeline of experimental weight-loss drugs, and the company said it expects to have data from the Phase 2 MariTide trial late this year."}, {"date": "20240502143323", "headline": "UPDATE 1-Amgen first-quarter profit dips 1%, revenue rises 22%", "summary": "Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth.  The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data.  The results were \"essentially in-linish ... although not anything significant for the Street given that it is still early in the year,\" David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email."}, {"date": "20240502151205", "headline": "Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript", "summary": "Amgen, Inc. (NASDAQ:NASDAQ:AMGN) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - Chairman,..."}, {"date": "20240502152127", "headline": "Amgen, DraftKings, Live Nation: Trending tickers", "summary": "Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith"}, {"date": "20240502152926", "headline": "Amgen Soars After CEO Gives Update on Experimental Obesity Drug", "summary": "(Bloomberg) -- Amgen Inc.\u2019s shares soared in late trading after its chief executive officer said he was \u201cvery encouraged\u201d by early results from a study of the company\u2019s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesBiden Calls Ally Japan \u2018Xenophobic\u2019 Along With China, RussiaIn Jamie Dimon's America, t"}, {"date": "20240502154232", "headline": "Amgen Inc (AMGN) Q1 2024 Earnings: Aligns with EPS Projections Amid Revenue Growth and Challenges", "summary": "Insight into Amgen's Financial Performance and Future Outlook"}, {"date": "20240502160007", "headline": "Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings", "summary": "The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals."}, {"date": "20240502165521", "headline": "Amgen Is 'Very Encouraged' With Its Obesity Study; Shares Rocket 13%", "summary": "Amgen stock popped late Thursday despite its profit beat as investors watch its potential rivals to Lilly and Novo drugs."}, {"date": "20240502183200", "headline": "GLOBAL BRIEFING: Apple shares climb as firm announces buyback", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502192400", "headline": "Amgen, Apple share gains lead Dow's 450-point rally", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502195800", "headline": "Amgen Inc (AMGN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic Advances", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502204800", "headline": "Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502213400", "headline": "What You Missed On Wall Street On Friday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502213900", "headline": "Amgen just upgraded at Barclays, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502221700", "headline": "Biggest stock movers today: AAPL, SQ, and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502223542", "headline": "Amgen: slight decline in Q1 EPS", "summary": "Amgen reported non-GAAP EPS for the first three months of 2024 down 1% to $3.96 on Thursday evening, with non-GAAP operating margin down 5.1 points to 43.2% on revenues up 22% to $7.4 billion.The..."}, {"date": "20240502230400", "headline": "Why Apple Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502233000", "headline": "William Blair gets more bullish on Amgen, upgrades shares", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502234201", "headline": "Amgen shares jump after teasing 'encouraging' weight loss data", "summary": "U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company teased encouraging data for its experimental obesity drug, igniting investor hopes but leaving Wall Street..."}, {"date": "20240502234400", "headline": "RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502234800", "headline": "Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503000800", "headline": "Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503001000", "headline": "Wall Street Looks To Feed Off Apple's Post-Earnings Power But Key Jobs Data May Upset The Cart: Analyst Says 'A Lot Of These Clouds Will Lift' If This Happens", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503001100", "headline": "William Blair upgrades Amgen on confidence in upcoming obesity data", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503003900", "headline": "Amgen price target raised by $23 at UBS, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503004600", "headline": "AMGN Earnings: Amgen Surges After Raised Forecast, Weight Loss Drug Update", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503004600", "headline": "Amgen up due to positive obesity data, says Jefferies", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503010700", "headline": "Amgen (AMGN) Receives a Buy from Piper Sandler", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503010900", "headline": "Oppenheimer Remains a Buy on Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503021300", "headline": "Amgen price target raised by $39 at Morgan Stanley, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503022100", "headline": "Amgen \u2018very encouraged\u2019 by data from weight-loss-drug trial, as stock jumps", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503023000", "headline": "Dow Jones Industrial Average Gains 450 Points As Investors Up Rate Cut Bets After Softer NFP", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503024521", "headline": "Stocks to Watch Friday: Apple, Amgen, Block", "summary": "\u2197\ufe0f **Apple (AAPL)**: The iPhone maker authorized $110 billion in stock buybacks and forecast a return to revenue growth in the current quarter. Apple shares climbed 6% in premarket trading. \u2197\ufe0f **Amgen (AMGN)**: The drug manufacturer's chief executive said he was \u201cvery encouraged\u201d by early data from a trial for an obesity treatment."}, {"date": "20240503025500", "headline": "Early notable gainers among liquid option names on May 3rd", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503030300", "headline": "Biggest stock movers today: WOW, AAPL, SQ, and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503032100", "headline": "Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503032700", "headline": "These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Block, Coinbase, Cloudflare, Fortinet, and More", "summary": "Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen \u2018very encouraged\u2019 by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year."}, {"date": "20240503033700", "headline": "Amgen stock rallies 13% on GLP-1 weight-loss drug update", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503034600", "headline": "AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503040200", "headline": "Amgen\u2019s obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to come", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503040200", "headline": "Dow's 525-point rally highlighted by gains in Amgen, Apple shares", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503040200", "headline": "Amgen, Apple share gains lead Dow's 360-point climb", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503041000", "headline": "Amgen price target lowered by $4 at RBC Capital, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503041400", "headline": "Amgen price target raised by $10 at BofA, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503042100", "headline": "Why Is WideOpenWest (WOW) Stock Up 30% Today?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503043500", "headline": "Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Kura Oncology (KURA) and Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503045900", "headline": "What You Missed On Wall Street This Morning", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503052600", "headline": "BMO Capital Reaffirms Their Buy Rating on Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503053400", "headline": "William Blair, Barclays upgrade Amgen following GLP-1 drug update", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503062400", "headline": "Amgen shares soar as executives outline obesity drug push", "summary": "The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen\u2019s market value."}, {"date": "20240503063100", "headline": "Apple, Amgen rise; Expedia, Fortinet fall, Friday, 5/3/2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503064000", "headline": "10 Health Care Stocks Whale Activity In Today's Session", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503065700", "headline": "Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503065825", "headline": "US STOCKS-Wall St set to open sharply higher on soft jobs data", "summary": "Wall Street's main indexes were set to open higher on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen on upbeat corporate updates added support.  The Labor Department report showed U.S. nonfarm payrolls increased by 175,000 jobs in April, compared with expectations for an increase of 243,000, according to economists polled by Reuters."}, {"date": "20240503073257", "headline": "Amgen upgraded, Peloton downgraded: Wall Street's top analyst calls", "summary": "Amgen upgraded, Peloton downgraded: Wall Street's top analyst calls"}, {"date": "20240503074500", "headline": "Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending", "summary": "Amgen released its Q1'24 earnings earlier today with revenues increasing 22% YoY to $7.45bn, with non-GAAP net income of $2.14bn. Explore more details here."}, {"date": "20240503075656", "headline": "These Two Stocks Are Driving the Dow Friday", "summary": "The Dow was up 524 points, or 1.4%, in recent trading.  Amgen stock was up 12.4% after the firm provided an encouraging update on injectable obesity drug MariTide.  With recent gains, Amgen added around 234 points to the Dow, alone."}, {"date": "20240503081106", "headline": "Amgen surges over confidence in early obesity drug results", "summary": "Shares of Amgen (AMGN) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development to treat obesity. The pharmaceutical giant beat first-quarter revenue estimates while reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins The Morning Brief to break down the latest developments from Amgen and its outlook on use cases for the drug in question, MariTide. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino"}, {"date": "20240503083107", "headline": "US STOCKS-Wall St gains after soft jobs data allays rate jitters", "summary": "Wall Street's main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen on upbeat corporate updates added support.  U.S. job growth slowed more than expected in April and the increase in annual wages fell below 4% for the first time in nearly three years, while the unemployment rate stood at 3.9% compared with expectations that it would remain steady at 3.8%."}, {"date": "20240503084200", "headline": "Amgen Stock Is Having Its Best Day Since 2009. Why Wall Street Is Excited About Its Weight-Loss Drug.", "summary": "The company is trying to carve a niche in a rapidly growing obesity-drug market that\u2019s currently dominated by Eli Lilly and Novo Nordisk."}, {"date": "20240503085100", "headline": "Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.", "summary": "Amgen\u2019s progress on its experimental weight-loss drug offered investors a reminder that Novo Nordisk isn\u2019t the only game in town.  Amgen\u2019s jumped some 13%.  Amgen late Thursday gave some brief but bullish commentary on its drug candidate, MariTide."}, {"date": "20240503092359", "headline": "Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript", "summary": "Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript May 2, 2024 Amgen Inc. beats earnings expectations. Reported EPS is $3.96, expectations were $3.88. Amgen Inc. isn\u2019t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: My name is Julianne, and I will [\u2026]"}, {"date": "20240503093526", "headline": "Weight-loss drug competition heats up. Is Wegovy in trouble?", "summary": "The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard J\u00f8rgensen \u2014 Novo Nordisk makes Wegovy and Ozempic \u2014 and Eli Lilly (LLY) CEO Dave Ricks \u2014 Eli Lilly makes Zepbound and Mounjaro \u2014 to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl"}, {"date": "20240503094800", "headline": "Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update", "summary": "Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is \"very encouraged\" by interim data from the phase II study on obesity candidate MariTide."}, {"date": "20240503101334", "headline": "US STOCKS-Wall St rallies after soft jobs data allays rate jitters", "summary": "Wall Street's main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen also helped.  U.S. job growth slowed more than expected in April and the increase in annual wages fell below 4% for the first time in nearly three years."}, {"date": "20240503101434", "headline": "Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition", "summary": "Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition"}, {"date": "20240503101547", "headline": "Dow Jones Jumps 400 Points As Apple Stock Surges; Nvidia Jumps Again, Tempts New Buyers", "summary": "A weak April jobs report fueled a wave of buying in the stock market today. Apple and Amgen were strong gainers in the Dow Jones."}, {"date": "20240503102000", "headline": "NEW YORK MARKET CLOSE: Dow up as soft jobs data revives rate cut hopes", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503110032", "headline": "Interest rate cuts could switch \u2018from stroll to a sprint\u2019 after US jobs surprise", "summary": "Traders have pulled forward their expectations for the first interest rate cuts in the US as the economy added fewer jobs than expected."}, {"date": "20240503125308", "headline": "Analyst unveils Amgen stock price target after weight-loss drug data", "summary": "Here's what could happen next to Amgen shares."}, {"date": "20240503145100", "headline": "These Stocks Moved the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More", "summary": "Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen \u2018very encouraged\u2019 by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year."}, {"date": "20240503150725", "headline": "Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market", "summary": "Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate."}, {"date": "20240503161534", "headline": "Why Amgen Stock Zoomed Nearly 12% Higher Today", "summary": "The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop."}, {"date": "20240503213935", "headline": "SCHD: A Must-Have In Every Dividend Portfolio", "summary": "Schwab U.S. Dividend Equity ETF (SCHD) offers diversification and resilience with a focus on healthy dividend-paying companies, but lower total returns. Read more here."}, {"date": "20240503230341", "headline": "Decoding Amgen Inc (AMGN): A Strategic SWOT Insight", "summary": "Insightful Analysis of Amgen Inc's Strengths, Weaknesses, Opportunities, and Threats"}, {"date": "20240504031302", "headline": "Amgen Could Become A Real Contender In The Obesity Market", "summary": "Amgen's shares surge on positive phase 2 trial results for obesity candidate MariTide, increasing its potential as a strong player in the market."}, {"date": "20240504063300", "headline": "Unveiling Amgen (AMGN)'s Value: Is It Really Priced Right? A Comprehensive Guide", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240504072609", "headline": "Amgen First Quarter 2024 Earnings: EPS Misses Expectations", "summary": "Amgen ( NASDAQ:AMGN ) First Quarter 2024 Results Key Financial Results Revenue: US$7.45b (up 22% from 1Q 2023). Net..."}]}